logo
Plus   Neg
Share
Email

HAIR Falls, NVCN Touches New Low, Mark Your Calendar For NDRA

pharmadown-nov28-lt.jpg

The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Arsanis Inc. (ASNS)

Lost 25.73% to close Wednesday's (Nov.28) trading at $3.06.

News: After gaining as much as 288% on Nov.27, following the merger news, the stock is giving back some of its gains.

Recent event:

On Nov.27, the Company entered into a definitive agreement with privately-held X4 Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused developing novel therapeutics for rare diseases and cancer, under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary of Arsanis in an all-stock transaction.

The merger would result in a combined company operating under the X4 Pharmaceuticals name that will focus on the development and commercialization of X4's lead product candidate, X4P-001, and the advancement of X4's pipeline of treatments for rare diseases of the immune system and rare cancers.

X4 Pharma's lead product candidate is X4P-001, which is expected to move into phase III trial in WHIM syndrome in the first half of 2019.

WHIM syndrome, or Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis syndrome is a rare genetic, primary immunodeficiency disease where patients become susceptible to certain types of viral and bacterial infections due to genetic mutations in the CXCR4 receptor gene.

2. Neovasc Inc. (NVCN)

Lost 17.10% to close Wednesday's trading at $0.83. The stock touched a 52-week low of $0.80 in intraday trading.

News: No news

Recent event:

On November 14, the Company reported financial results for the third quarter ended September 30, 2018.

Revenues decreased 65% to $480,540 for the recent third quarter from $1.37 million for the same period in 2017. Last December, the Company closed its contract manufacturing and consulting services business and is now focused on the commercialization of its own product, the Reducer for the treatment of refractory angina.

Sales of the Reducer in the recent third quarter were $480,540 compared to $334,208 for the same period in 2017, representing an increase of 44%.

3. Biocept Inc. (BIOC)

Biocept is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.

Lost 14.18% to close Wednesday's trading at $1.15.

News: No news

Recent event:

On November 13, the Company reported financial results for the third quarter ended September 30, 2018.

Revenues for the third quarter of 2018 were $762,000, compared with $1.1 million for the third quarter of 2017. Biocept reported 964 total samples in the third quarter of 2018, compared with 1,343 total samples in the third quarter of 2017.

4. ENDRA Life Sciences Inc. (NDRA)

ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS) system that will help clinicians to visualize tissue function, composition, and monitor a variety of therapeutic interventions at the point of care. The first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease.

Lost 13.78% to close Wednesday's trading at $3.38.

News: No news

Recent event:

On November 13, the Company closed its underwritten public offering of 1.21 million shares of common stock at an offering price of $3.90 per share.

The underwriter exercised in full its over-allotment option to purchase an additional 180,750 shares of common stock. The gross proceeds from the public offering were approximately $5.4 million.

Near-term Catalyst:

The first human studies with the TAEUS clinical system targeting Non-Alcoholic Fatty Liver Disease are expected to yield results in December 2018.

5. Restoration Robotics Inc. (HAIR)

Restoration Robotics is a medical device company developing and commercializing ARTAS and ARTAS iX Robotic Hair Restoration Systems.

Lost 10.76% to close Wednesday's trading at $1.41.

News: No news

Recent event:

On November 5, the Company announced financial results for the third quarter ended September 30, 2018.

Net loss for the third quarter of 2018 was $7.1 million or $0.20 per share on revenue of $4.8 million. In the third quarter of 2018, the Company sold 11 ARTAS iX Robotic Hair Restoration Systems, including 10 in the U.S.

The net loss for the third quarter of 2017 was $6.6 million or $4.07 per share on revenue of $4.2 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT